Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Authors: Bachelot, T., Bouzid, K., Campone, M., Desmoulins, I., Coudert, B., Bondarenko, I., Nowecki, Z., Glogowska, I., Ciruelos Gil, E., Errihani, H., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Paluch-Shimon, S., Wardley, A., Schneeweiss, A., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Puglisi, F., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Miles, D., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhász, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vásques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M.J., Illarramendi Mañas, J., Martinez De Dueñas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcón Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., McCarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Böess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferraù, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., López, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Müller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeño, M., Ruohola, J., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Grischke, E.-M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D’Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., García Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M.H., Martínez Jañez, N., Mele Olive, M., McAdam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Grève, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kütner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Lück, H.-J., Zahm, D.-M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C.H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kühn, T., Ober, A., Repp, R., Schröder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Pérez Martínez, M., van de Wouw, A.J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Antón Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florián Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Björneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodríguez, R., Ciruelos, E., Peretz-Yablonski, T., Merot, J.-L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., Klingbiel, D.

Source: In Annals of Oncology October 2021 32(10):1245-1255

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK

Authors: Khoja, L. ^∗, Nolan, K. ^†, Mekki, R. ^†, Milani, A. ^‡, Mescallado, N. ^∗, Ashcroft, L. ^§, Hasan, J. ^∗, Edmondson, R. ^¶, Winter-Roach, B. ^∗, Kitchener, H.C. ^¶, Mould, T. ^‡, Hutson, R. ^†, Hall, G. ^†, Clamp, A.R. ^∗, Perren, T. ^†, Ledermann, J. ^‡, Jayson, G.C. ^∗

Source: In Clinical Oncology December 2016 28(12):760-765

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer

Authors: Rustin, G. ^*, Reed, N., Jayson, G.C., Ledermann, J.A., Adams, M., Perren, T., Poole, C., Lind, M., Persic, M., Essapen, S., Gore, M., Calvert, H., Stredder, C., Wagner, A., Giurescu, M., Kaye, S.

Source: In Annals of Oncology November 2011 22(11):2411-2416

Implications of ejection fraction value for trastuzumab

Authors: Schlosshan, D, Dickinson, C, Sapsford, R, Dodwell, D, Perren, T

Source: BMJ: British Medical Journal, 2006 Sep . 333(7570), 704-704.

Access URL: https://www.jstor.org/stable/40700891

A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial

Authors: Sirohi, B., A'Hern, R., Coombes, G., Bliss, J.M., Hickish, T., Perren, T., Crawford, M., O'Brien, M., Iveson, T., Ebbs, S., Skene, A., Laing, R., Smith, I.E. ^*

Source: In Annals of Oncology August 2010 21(8):1623-1629

p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial

Authors: Di Leo, A. ^*, Tanner, M., Desmedt, C., Paesmans, M., Cardoso, F., Durbecq, V., Chan, S., Perren, T., Aapro, M., Sotiriou, C., Piccart, M.J., Larsimont, D., Isola, J.

Source: In Annals of Oncology June 2007 18(6):997-1003

Die Fraktur des Processus lateralis tali (Snowboarder's Foot): Eine Übersicht

Alternate Title: Fracture of the lateral process of the talus (snowboarder's foot) – A review (English)

Authors: Camathias, C., Valderrabano, V., Pagenstert, G., Perren, T., Friederich, N., Hintermann, B.

Source: In Fuss und Sprunggelenk 2006 4(3):184-193

Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer

Authors: Poole, C.J. ^{1, 3, 4, *}, Perren, T. ², Burton, A. ¹, Jordan, S.D. ^{1, 4}, Jenkins, A.H. ², Mould, J.J. ³, Spooner, D.A. ³, Luesley, D. ^{4, 5}, Chan, K.K. ⁵, Sturman, S. ⁴, Earl, H.M. ⁶

Source: In Annals of Oncology December 2000 11(12):1603-1608

Preponderant impact of the chemosensitivity assessed by the modeled CA-125 kinetic parameter KELIM on the success of the first line treatment: Pooled analysis of AGO-OVAR 7, AGO-OVAR 9 and ICON7 trials--a GINECO-GINEGEPS study

Authors: You, B., Tod, M., Leary, A., Ray-Coquard, I., Lortholary, A., Hardy-Bessard, A.C., Perren, T., Cook, A., Pfisterer, J., Bois, A.D., Kurzeder, C., Burges, A., Peron, J., Freyer, G., Colomban, O.

Source: In Gynecologic Oncology October 2020 159 Supplement 1:339-340

PCN219 - CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC HORMONE RECEPTOR POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE (HER2-) BREAST CANCER IN CLINICAL PRACTICE: RETROSPECTIVE ANALYSIS FROM LEEDS CANCER CENTRE

Authors: Cheeseman, S., Thompson, M., Riaz, M., Twelves, C., Perren, T., Ahat-Donker, N., Sopwith, W., Myland, M., Lee, A., Przybysz, R., Turner, S., Hall, G.

Source: In Value in Health October 2018 21 Supplement 3:S51-S51

1340P - Clinical utility of complex multi-platform profiling in metastatic cancer patients

Authors: Garcia Foncillas, J., Aftimos, P.G., Barthelemy, P., Bellmunt, J., Berchem, G., Camps, C., de las Peñas, R., Finzel, A., Hervonen, J.P., Joensuu, T., Kong, A., Mackay, J., Mikropoulos, C., Mokbel, K., Mouysset, J.-L., Perren, T.-J., Guitti, G., Laes, J.-F.

Source: In Annals of Oncology October 2018 29 Supplement 8

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

929O_PR - ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis

Authors: Clamp, A.R., McNeish, I., Dean, A., Gallardo, D., Weon-Kim, J., O'Donnell, D., Hook, J., Coyle, C., Blagden, S.P., Brenton, J., Naik, R., Perren, T., Sundar, S., Cook, A., James, E., Swart, A.M., Stenning, S., Kaplan, R., Ledermann, J.

Source: In Annals of Oncology September 2017 28 Supplement 5:v627-v627

961P - ICON7: Ovarian cancer, platinum second-line chemotherapy and overall survival

Authors: Cook, A., Embleton, A., Jayson, G., Kaplan, R., Kristensen, G., Parmar, M.K., Pfisterer, J., Pujade-Lauraine, E., Oza, A.M., Perren, T.

Source: In Annals of Oncology September 2017 28 Supplement 5:v343-v343

861P - ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer

Authors: James, E.C., Hook, J., Stenning, S., Cook, A., Coyle, C., Petrie, J., Kaplan, R., McNeish, I., Perren, T., Naik, R., Banerjee, S., Ledermann, J.A., Clamp, A.

Source: In Annals of Oncology 1 October 2016 27 Supplement 6:vi297-vi297

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.